Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN008 plus Re-irradiation in Recurrent Glioblastoma
NCT03746288Phase 2Unknown
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Nov 2018
- Primary completion
- Jul 2021
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 2 trial of asunercept in glioblastoma (GBM), sponsored by CANbridge Pharmaceuticals Inc.. Status: unknown.
02
Drugs
asunercept
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03746288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746288.